Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	393K 352K 324K 293K 548K 37.31M 558K 3.86M 1.55M 19.62M 1.47M 1.44M 61.89M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-3.83M -3.43M -3.16M -2.86M -5.35M -364M -5.45M -37.65M -15.11M -191M -14.38M -14.08M -604M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

10-01	SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-26	Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026	CI
08-17	Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd.	CI
08-05	SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome	CI
07-29	Scisparc Ltd. Announces Establishment of Scientific Advisory Board	CI
06-30	Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in funding from SciSparc Ltd.	CI
04-30	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-17	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-12	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI

10-22	SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome	GL
10-19	SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications	GL
10-15	SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies	GL
10-08	SciSparc: Subsidiary NeuroThera Labs CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture	AQ
10-07	SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture	GL

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	10/01/2022
Amitay Weiss CEO	Chief Executive Officer	62	21/08/2020
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	08/02/2016

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	10/01/2022
Itschak Shrem CHM	Chairman	79	21/09/2025
Lior Vider BRD	Director/Board Member	50	21/08/2020

SciSparc Ltd. Stock OTC Markets

Stocks

TRPXD

US80909J1025

Pharmaceuticals

Valuation: SciSparc Ltd.

Latest news: SciSparc Ltd.

Press Releases: SciSparc Ltd.

News in other languages: SciSparc Ltd.

Quotes and Performance

Managers and Directors: SciSparc Ltd.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/6/26	Itschak Shrem	Sell	Chairman	-462	0.0806%
18/3/26	Amnon Ben Shay	Other	Director	3,652	0.0839%
18/3/26	Oz Adler	Other	Chief Executive Officer	11,064	0.2543%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCISPARC LTD.	-19.03%	-15.79%	-	-	393K
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.66%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+83.74%	658B
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+106.98%	521B
ROCHE HOLDING AG	-1.40%	+0.43%	+53.45%	+67.21%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.38%	369B
NOVARTIS AG	-1.48%	+3.34%	+32.40%	+55.61%	307B
ASTRAZENECA PLC	-0.81%	+7.78%	+12.05%	+33.70%	290B
AMGEN INC.	+1.15%	+6.09%	+56.15%	+78.66%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+112.84%	212B
Average	-1.24%	+5.90%	+46.07%	+82.20%	473.55B
Weighted average by Cap.	+1.13%	+6.60%	+50.13%	+98.77%

	2024	2025
Net sales	1.31 1.17 1.08 0.97 1.82 124.01 1.86 12.83 5.15 65.23 4.9 4.8 205.71	0.86 0.77 0.71 0.64 1.19 81.28 1.22 8.41 3.38 42.75 3.21 3.14 134.83
Net income	-6.28M -5.63M -5.18M -4.69M -8.77M -597M -8.93M -61.73M -24.78M -314M -23.58M -23.08M -990M	-12.18M -10.91M -10.03M -9.09M -16.99M -1.16B -17.31M -120M -48.03M -608M -45.71M -44.73M -1.92B
Net Debt	-2.01M -1.8M -1.66M -1.5M -2.81M -191M -2.86M -19.76M -7.93M -100M -7.55M -7.39M -317M	-4.22M -3.78M -3.48M -3.15M -5.9M -401M -6.01M -41.51M -16.66M -211M -15.86M -15.52M -665M